Relief Therapeutics Secures up to $11 Million From Royalty Sales
Relief Therapeutics Secures up to $11 Million From Royalty Sales
Non-dilutive funding to support RLF-TD011 clinical development and pipeline advancement
非稀釋性融資以支持RLF-TD011的臨床開發和管道推進。
GENEVA, SWITZERLAND / ACCESSWIRE / August 5, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the signing and closing of a definitive agreement with SWK Funding LLC (SWK), a wholly-owned subsidiary of SWK Holdings Corporation, for the sale of royalty interests in OLPRUVA, GOLIKE and CAMBIA in exchange for up to U.S. $11 million in cash consideration.
瑞士日內瓦/ ACCESSWIRE / 2024年8月5日 / RELIEF THERAPEUTICS Holding SA(SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY)(Relief或公司)是一家生物製藥公司,致力於爲特定的專業,未滿足和罕見疾病提供創新的治療選擇。今天宣佈與SWk Financing LLC(SWK)簽訂和完成有關OLPRUVA,GOLIKE和CAMBIA的專利權益出售的最終協議,以換取高達1100萬美元的現金考慮代價。
The transaction provides the Company with non-dilutive funding to advance its pipeline, including the clinical development of its patent-protected hypochlorous acid topical spray, RLF-TD011, for treating epidermolysis bullosa. The funding will also be used for working capital and general corporate purposes.
該交易爲公司提供了非稀釋資金,以推進其管道,包括專利保護的次氯酸頂部噴霧RLF-TD011的臨床開發,用於治療表皮鬆解性水泡病。此資金還將用於營運資金和一般企業用途。
Under the terms of the agreement, Relief received $5.75 million from SWK and may receive an additional $5.25 million contingent on the achievement of near-term milestones. These include $3.25 million if OLPRUVA's quarterly net sales reach $1.5 million by the end of the third quarter of 2025, and $2 million if Zevra Therapeutics Inc. (Zevra) secures this year NDA approval from the U.S. FDA for arimoclomol to treat Niemann-Pick Disease Type C (NPC). The FDA Genetic Metabolic Diseases Advisory Committee recently voted in favor of arimoclomol's effectiveness for treating NPC; their recommendation will be considered in the FDA's decision expected on September 21, 2024.
根據協議的規定,Relief從SWk獲得575萬美元,並可能獲得最多525萬美元的附加賠償,包括如果OLPRUVA季度淨銷售額在2025年第三季度結束時達到150萬美元的325萬美元,以及如果Zevra Therapeutics Inc.(Zevra)獲得用於治療尼曼 - 皮克氏症C型(NPC)的arimoclomol今年NDA批准,200萬美元。FDA遺傳代謝疾病諮詢委員會最近投票贊成arimoclomol治療NPC的有效性,他們的建議將在預計於2024年9月21日的FDA決定中予以考慮。
SWK acquired all future OLPRUVA royalties from Relief's August 2023 agreement with Acer Therapeutics Inc. (Acer), a wholly-owned subsidiary of Zevra. Neither SWK nor Relief are entitled to any future royalties associated with arimoclomol from Acer. Additionally, SWK acquired all future royalties and milestone payments from the March 2024 license agreement with Eton Pharmaceuticals Inc. for the commercialization of the GOLIKE product family in the United States. Relief retains significant upside potential, with SWK returning to Relief 80% of OLPRUVA royalties over $2.25 million annually and all royalties over $4.5 million. For GOLIKE, SWK will return 80% of GOLIKE royalties over $1.32 million annually and all royalties over $1.98 million. In any case, the agreement will terminate, and all royalties will revert to Relief once SWK has received 2.75 times its invested capital.
SWk從Relief與Acer Therapeutics Inc.(Acer)於2023年8月達成的協議中收購了所有未來的OLPRUVA版稅。經Acer全資子公司Zevra的授權,SWk或Relief均不享有任何與arimoclomol有關的未來版稅。此外,SWk從2024年3月與Eton Pharmaceuticals Inc.的許可協議中收購了所有未來的版稅和里程碑付款,用於在美國推廣GOLIKE產品系列。Relief保留了巨大的上行潛力,SWk每年超過225萬美元的OLPRUVA版稅超過80%,在450萬美元的全部版稅。對於GOLIKE,SWk將每年超過132萬美元的GOLIKE版稅超過80%,並超過198萬美元的全部版稅。無論如何,一旦SWk獲得2.75倍的投資資本,協議將終止,所有版稅將歸還給Relief。
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief's portfolio offers a balanced mix of marketed, revenue-generating products, proprietary, globally patented TEHCLO and Physiomimic platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare skin diseases, rare metabolic disorders, and rare respiratory diseases. In addition, Relief is commercializing several legacy products via licensing and distribution partners. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit .
關於RELIEF
Relief是一家商業化階段的生物製藥公司,致力於推進治療範式,提高治療效果,安全性和便利性,從而造福於患有特定專業和罕見疾病的患者。 Relief的組合產品提供了平衡的市場,產生收入,專有,全球專利TEHCLO和Physiomimic平台技術以及定向臨床開發管道,包括三個核心治療領域:罕見的皮膚病,罕見的代謝性疾病和罕見的呼吸道疾病。此外,Relief通過授權和分銷合作伙伴商業化了數種傳統產品。 總部設在日內瓦,Relief在SIX Swiss Exchange上市,代碼爲RLF,在OTCQb上引用代碼爲RLFTF和RLFTY。 有關更多信息,訪問。
ABOUT SWK
SWK Holdings Corporation (SWKH.OB) is a life science focused specialty finance company partnering with small- and mid-sized commercial-stage healthcare companies. SWK provides non-dilutive financing to fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products. SWK's solutions include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases. Additional information on SWK is available .
關於SWk
SWk Holdings Corporation(SWKH.OB)是一家專注於生命科學的專業金融公司,與小型和中型商業化階段醫療保健公司合作。 SWk提供非稀釋性融資,以推動生命拯救和生命增強型醫療技術和產品的開發和商業化。 SWK的解決方案包括結構化債務,傳統版稅變現,合成版稅交易和資產購買。 可在上獲取有關SWk的其他信息。
CONTACT :
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
contact@relieftherapeutics.com
聯繫方式 :
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
contact@relieftherapeutics.com
DISCLAIMER
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, including its ability to achieve its corporate, development and commercial goals, and other factors which could cause the actual results, financial condition, performance or achievements of Relief to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. A number of factors, including those described in Relief's filings with the SIX Swiss Exchange and the U.S. Securities and Exchange Commission (SEC), could adversely affect Relief. Copies of Relief's filings with the SEC are available on the SEC EDGAR database at www.sec.gov . Relief does not undertake any obligation to update the information contained herein, which speaks only as of this date.
免責聲明
本新聞稿包含前瞻性陳述。 前瞻性陳述涉及已知和未知的風險,不確定性,包括其實現其公司,開發和商業目標的能力,以及可能導致Relief的實際結果,財務狀況,績效或成就與任何未來結果,績效或預期的前瞻性陳述有實質不同的因素。諸如上述因素的數量,在Relief與美國證券交易委員會(SEC)的SIX Swiss Exchange和SEC的文件中描述,可能會對Relief產生不利影響。 Relief的文件備份可在SEC EDGAR數據庫中查詢www.sec.gov。 Relief不承擔更新此處所含信息的任何義務,該信息僅於本日期有效。
Additional features:
其他特色:
File: Ad hoc
文件:Ad hoc
SOURCE: Relief Therapeutics Holdings AG
SOURCE:Relief Therapeutics Holdings AG
譯文內容由第三人軟體翻譯。